Hoping For A Higher Take: FS KKR Capital Corp. (FSK), Ritter Pharmaceuticals, Inc. (RTTR)

FS KKR Capital Corp. (NYSE:FSK) has its shares plummet by -20.3% or $1.47 from its all-time high of $7.24. The drop in the price of the shares saw it stand at $5.77 per share. FSK has been trading at a low of $5.09 over the past one year but it surged by 13.36% or $0.68 to reach the $5.77 mark. Following the massive rise in stock price, FSK received more attention from investors and analysts. On Thursday, the stock plunged by 1.23%, which caused investors and analysts to excite about it. Following the plunge in price, the FSK beta stands at 0, implying that its volatility level has gone down by 1 back of the general market. A look at the stock’s 200-day moving average shows that it is -4.36% below while its 50-day moving average shows that it is currently -1.17% below. Compared to 1.63% average daily volatility of past month, the stock’s average volatility for this week has increased by 0.0700000000000001 as the volatility level currently stands at 1.7%.

Over the past seven days, the stock has witnessed a price dip by -2.53%. This massive drop in stock price has caught the attention of both investors and market traders. The stock has performed poorly over the past 52 weeks, dropping by -18.13% during that time frame and is now up by 11.39% since this point this year. FSK has fell by -0.17% over the past 30 days, with its equity price losing% of its value over the past ninety days. These figures add up to see the stock record a shortfall of -4.79% over the past six months.

Market analysts from research firms still remain bullish about the short-term performance of FSK. Most of them are of the view that the stock would be able to reach $7 over the next 12 months. If that happens, then the stock would witness a 21.32% rise in its price and that would see the stock’s market cap hit an astonishing $4 Billion. Analysts view this stock as a bearish at the moment as its average rating is 2.6. According to Reuters, many of the 4 analysts covering the stock at the moment believe it is a Buy. 3 of them rated FSK as a Hold while 1 of them either rated it as a Buy or a Strong Buy. However, 0 of them advised investors to sell the stock if they have it or shouldn’t buy it if they don’t possess any.

The stock’s technical analysis reveals that its 14-day Relative Strength Index (RSI) is currently in a neutral position as it was able to attain 46.58 points. The trading volume now standing at 2899179 shares. The increase of 979179 shares in trading volume shows that traders and investors have shown more interest in the stock over the past few weeks. During that trading session, the average trading volume of FSK was 1920000 shares, which is more than 1.51 times higher than its usual trading volume.

Ritter Pharmaceuticals, Inc. has seen its stock (NASDAQ:RTTR) surge by $0.03 or 10.32% to currently trade at $0.3. This rise in the price of the stock has seen it establish a strong support at $0.27 a share. If the stock price is to drop below that support level, then it would be followed by a bearish trend. A slip below $0.24 would be bad for RTTR as it would mean that the stock has lost 20% of its value. The stock going in the opposite direction and breaking past the resistance point to reach $0.31 would see it surge even higher. RTTR would attempt to surge past the upward resistance point which is set at $0.33 a share. RTTR has an average volatility of 9.82% over the past 30 days, while it has gained 16.67% of its value compared to its 52-weeks low point which stands at $0.25 on Sep 17, 2019. In the same breath, RTTR has lost 15% compared to its 52-weeks high point which currently stands at $0.255 a share reached on Oct 08, 2018.

Analysts have set a 1-year price target for this stock, with most of them expecting it to reach $6.5/share over the next 12 months. If that happens, then RTTR would witness a 2066.67% rise from its current price. The price of the stock has been moving between $0.255 and $0.299. Not all analysts believe it would hit that target though, as some of them expect it to trade lower, as low as $6 per share. In the same breath, one analyst believes that the stock is set to soar even higher than expected, as the price target was set at $7.

The stock is currently oversold as its Stochastic Oscillator (%D) is at 2.91%, which implies that a jump in price could be experienced soon. Its shares P/S ratio is below the 2.71 industry average and below the 1.04 by the wider market, as RTTR’s P/S ratio currently stands at 0. The stock’s estimated price-earnings (P/E) multiple is 0 which is also below the 12-month price-earnings (P/E) which stands at 0. Ritter Pharmaceuticals, Inc. has experienced a rise in its earnings, recording an increase rate of 4.9% in each quarter over the past five years.